274 related articles for article (PubMed ID: 31897875)
21. Adjuvant radiotherapy in patients with node-positive prostate cancer after radical prostatectomy.
Chen H; Qu M; Shi H; Dong Z; Wang Y; Gao X
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4925-4932. PubMed ID: 36308526
[TBL] [Abstract][Full Text] [Related]
22. Impact of Early Salvage Androgen Deprivation Therapy in Localized Prostate Cancer after Radical Prostatectomy: A Propensity Score Matched Analysis.
Park JW; Jang WS; Koh DH; Ham WS; Rha KH; Hong SJ; Choi YD
Yonsei Med J; 2018 Jul; 59(5):580-587. PubMed ID: 29869455
[TBL] [Abstract][Full Text] [Related]
23. Obesity, race, and long-term prostate cancer outcomes.
Vidal AC; Oyekunle T; Howard LE; De Hoedt AM; Kane CJ; Terris MK; Cooperberg MR; Amling CL; Klaassen Z; Freedland SJ; Aronson WJ
Cancer; 2020 Aug; 126(16):3733-3741. PubMed ID: 32497282
[TBL] [Abstract][Full Text] [Related]
24. The impact of time to metastasis on overall survival in patients with prostate cancer.
Frees S; Akamatsu S; Bidnur S; Khalaf D; Chavez-Munoz C; Struss W; Eigl BJ; Gleave M; Chi KN; So A
World J Urol; 2018 Jul; 36(7):1039-1046. PubMed ID: 29488095
[TBL] [Abstract][Full Text] [Related]
25. Prostate weight and prostate cancer outcomes after radical prostatectomy: Results from the SEARCH cohort study.
Barlow SK; Oyekunle T; Janes JL; De Hoedt AM; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Klaassen ZW; Terris MK; Freedland SJ; Csizmadi I
Prostate; 2022 Feb; 82(3):366-372. PubMed ID: 34905632
[TBL] [Abstract][Full Text] [Related]
26. Does docetaxel prolong survival of patients with non-metastatic castration-resistant prostate cancer?
Ito K; Kimura T; Onuma H; Tabata R; Shimomura T; Miki K; Tomita M; Egawa S
Prostate; 2018 May; 78(7):498-505. PubMed ID: 29473179
[TBL] [Abstract][Full Text] [Related]
27. Subclassification of pathologically organ-confined (pT2) prostate cancer does not significantly predict postoperative outcomes in Korean males.
Lee MH; Lee S; Hong SK; Byun SS; Lee SE
Investig Clin Urol; 2020 Jan; 61(1):35-41. PubMed ID: 31942461
[TBL] [Abstract][Full Text] [Related]
28. Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes.
Preisser F; Chun FKH; Pompe RS; Heinze A; Salomon G; Graefen M; Huland H; Tilki D
Eur Urol; 2019 Jul; 76(1):106-114. PubMed ID: 30772034
[TBL] [Abstract][Full Text] [Related]
29. Increased Prostate Cancer Glucose Metabolism Detected by
Lavallée E; Bergeron M; Buteau FA; Blouin AC; Duchesnay N; Dujardin T; Tiguert R; Lacombe L; Fradet V; Makao-Nguile M; Fradet Y; Beauregard JM; Pouliot F
Eur Urol Focus; 2019 Nov; 5(6):998-1006. PubMed ID: 29609897
[TBL] [Abstract][Full Text] [Related]
30. Predicting factors for progression to castration resistance prostate cancer after biochemical recurrence in patients with clinically localized prostate cancer who underwent radical prostatectomy.
Hashimoto T; Nakashima J; Kashima T; Yamaguchi Y; Satake N; Nakagami Y; Namiki K; Ohno Y
Int J Clin Oncol; 2020 Sep; 25(9):1704-1710. PubMed ID: 32500468
[TBL] [Abstract][Full Text] [Related]
31. Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer.
Howard LE; Moreira DM; De Hoedt A; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Freedland SJ
BJU Int; 2017 Nov; 120(5B):E80-E86. PubMed ID: 28371163
[TBL] [Abstract][Full Text] [Related]
32. Radical Prostatectomy in Metastatic Castration-resistant Prostate Cancer: Feasibility, Safety, and Quality of Life Outcomes.
Reichard CA; Gregg JR; Achim MF; Aparicio AM; Pettaway CA; Pisters LL; Ward JF; Davis JW; Chapin BF
Eur Urol; 2018 Aug; 74(2):140-143. PubMed ID: 29656854
[TBL] [Abstract][Full Text] [Related]
33. Intermediate-term cancer control outcomes in prostate cancer patients treated with robotic-assisted laparoscopic radical prostatectomy: a multi-institutional analysis.
Abdollah F; Dalela D; Sood A; Sammon J; Jeong W; Beyer B; Fossati N; Rogers CG; Diaz-Insua M; Peabody J; Haese A; Montorsi F; Graefen M; Briganti A; Menon M
World J Urol; 2016 Oct; 34(10):1357-66. PubMed ID: 26873596
[TBL] [Abstract][Full Text] [Related]
34. Is time to castration resistant prostate cancer a potential intermediate end-point for time to metastasis among men initiating androgen deprivation therapy for non-metastatic prostate cancer with rapid PSA doubling time (<9 months)?
Klaassen Z; Howard L; Wallis CJD; Janes JL; De Hoedt A; Aronson WJ; Polascik TJ; Amling CJ; Kane CJ; Cooperberg MR; Terris MK; Wu Y; Freedland SJ
Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):151-155. PubMed ID: 36050455
[TBL] [Abstract][Full Text] [Related]
35. Patients' preferences for delaying metastatic castration-resistant prostate cancer: Combining health state and treatment valuation.
Rentz AM; Mansukhani SG; Liu J; Lloyd AJ; Heidenreich S; Matza LS; Dawson NA; Shore N; Freedland SJ
Urol Oncol; 2021 Jun; 39(6):367.e7-367.e17. PubMed ID: 33736976
[TBL] [Abstract][Full Text] [Related]
36. The prognostic significance of OCT4 expression in patients with prostate cancer.
Kosaka T; Mikami S; Yoshimine S; Miyazaki Y; Daimon T; Kikuchi E; Miyajima A; Oya M
Hum Pathol; 2016 May; 51():1-8. PubMed ID: 27067776
[TBL] [Abstract][Full Text] [Related]
37. Prostate cancer in 432 men aged <50 years in the prostate-specific antigen era: a new outlook.
Gielchinsky I; Chang J; Cusick T; Delprado W; Nguyen Q; Yuen C; Savdie R; Böhm M; Haynes AM; Scheltema MJ; Stricker PD
BJU Int; 2018 Nov; 122 Suppl 5():35-41. PubMed ID: 30303599
[TBL] [Abstract][Full Text] [Related]
38. Natural History of Clinical Recurrence Patterns of Lymph Node-Positive Prostate Cancer After Radical Prostatectomy.
Moschini M; Sharma V; Zattoni F; Quevedo JF; Davis BJ; Kwon E; Karnes RJ
Eur Urol; 2016 Jan; 69(1):135-42. PubMed ID: 25865061
[TBL] [Abstract][Full Text] [Related]
39. Radical prostatectomy neutralizes obesity-driven risk of prostate cancer progression.
Schiffmann J; Salomon G; Tilki D; Budäus L; Karakiewicz PI; Leyh-Bannurah SR; Pompe RS; Haese A; Heinzer H; Huland H; Graefen M; Tennstedt P
Urol Oncol; 2017 May; 35(5):243-249. PubMed ID: 28161322
[TBL] [Abstract][Full Text] [Related]
40. Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer.
Briganti A; Joniau S; Gontero P; Abdollah F; Passoni NM; Tombal B; Marchioro G; Kneitz B; Walz J; Frohneberg D; Bangma CH; Graefen M; Tizzani A; Frea B; Karnes RJ; Montorsi F; Van Poppel H; Spahn M
Eur Urol; 2012 Mar; 61(3):584-92. PubMed ID: 22153925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]